Simvastatin and oseltamivir combination therapy does not improve the effectiveness of oseltamivir alone following highly pathogenic avian H5N1 influenza virus infection in mice

Virology

Volumn 439, Issue 1, 2013, Pages 42-46

  Belser, Jessica A ^a   Szretter, Kristy J ^a   Katz, Jacqueline M ^a   Tumpey, Terrence M ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

H5N1; Influenza virus; Mice; Oseltamivir; Simvastatin

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P40; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; OSELTAMIVIR; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; IN VIVO STUDY; INFLUENZA A (H1N1); INFLUENZA A (H5N1); MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS LOAD;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIVIRAL AGENTS; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; LUNG; MICE; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; SIMVASTATIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIRAL LOAD;

AVES; MUS; ORTHOMYXOVIRIDAE;

EID: 84874968369     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.01.017     Document Type: Article

References (32)

1. An S.-C., Xu L.-L., Li F.-D., Bao L.-L., Qin C., Gao Z.-C. Triple combinations of neuraminidase inhibitors, statins and fibrates benefit the survival of patients with lethal avian influenza pandemic. Med. Hypotheses 2011, 77:1054-1057.
2. Belser J.A., Wadford D.A., Pappas C., Gustin K.M., Maines T.R., Pearce M.B., Zeng H., Swayne D.E., Pantin-Jackwood M., Katz J.M., Tumpey T.M. Pathogenesis of pandemic influenza A (H1N1) and triple-reassortant swine influenza A (H1) viruses in mice. J. Virol. 2010, 84:4194-4203.
3. Blanc M., Hsieh W.Y., Robertson K.A., Watterson S., Shui G., Lacaze P., Khondoker M., Dickinson P., Sing G., Rodriguez-Martin S., Phelan P., Forster T., Strobl B., Muller M., Riemersma R., Osborne T., Wenk M.R., Angulo A., Ghazal P. Host defense against viral infection involves interferon mediated down-regulation of sterol biosynthesis. PLOS Biol. 2011, 9:e1000598.
4. Boyd A.R., Hinojosa C., Rodriguez P.J., Orihuela C.J. Impact of oral simvastatin therapy on acute lung injury in mice during pneumococcal pneumonia. BMC Microbiol. 2012, 12:73.
5. Brett S.J., Myles P., Lim W.S., Enstone J.E., Bannister B., Semple M.G., Read R.C., Taylor B.L., McMenamin J., Nicholson K.G., Nguyen-Van-Tam J.S., Openshaw P.J. Pre-admission statin use and in-hospital severity of 2009 pandemic influenza A(H1N1) disease. PLOS One 2011, 6:e18120.
6. Budd A., Alleva L., Alsharifi M., Koskinen A., Smythe V., Mullbacher A., Wood J., Clark I. Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob. Agents Chemother. 2007, 51:2965-2968.
7. Fedson D.S. Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clin. Infect. Dis.: Official Publ. Infect. Dis. Soc. Am. 2006, 43:199-205.
8. Ferraro S.A., Yakisich J.S., Gallo F.T., Tasat D.R. Simvastatin pretreatment prevents ambient particle-induced lung injury in mice. Inhalation Toxicol. 2011, 23:889-896.
9. Frost F.J., Petersen H., Tollestrup K., Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007, 131:1006-1012.
10. Govorkova E.A., Ilyushina N.A., McClaren J.L., Naipospos T.S., Douangngeun B., Webster R.G. Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. Antimicrob. Agents Chemother. 2009, 53:3088-3096.
11. Gower T.L., Graham B.S. Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro. Antimicrob. Agents Chemother. 2001, 45:1231-1237.
12. Gubareva L.V., Kaiser L., Hayden F.G. Influenza virus neuraminidase inhibitors. Lancet 2000, 355:827-835.
13. Ilyushina N.A., Hay A., Yilmaz N., Boon A.C., Webster R.G., Govorkova E.A. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob. Agents Chemother. 2008, 52:3889-3897.
14. Ilyushina N.A., Hoffmann E., Salomon R., Webster R.G., Govorkova E.A. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antiviral Ther. 2007, 12:363-370.
15. Jacobson J.R., Barnard J.W., Grigoryev D.N., Ma S.F., Tuder R.M., Garcia J.G. Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005, 288:L1026-1032.
16. Jain M.K., Ridker P.M. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nature reviews. Drug Discov. 2005, 4:977-987.
17. Kumaki Y., Morrey J.D., Barnard D.L. Effect of statin treatments on highly pathogenic avian influenza H5N1, seasonal and H1N1pdm09 virus infections in BALB/c mice. Future Virol. 2012, 7:801-818.
18. Kwak B., Mulhaupt F., Myit S., Mach F. Statins as a newly recognized type of immunomodulator. Nat. Med. 2000, 6:1399-1402.
19. Kwong J.C., Li P., Redelmeier D.A. Influenza morbidity and mortality in elderly patients receiving statins: a cohort study. PLOS One 2009, 4:e8087.
20. Leung B.P., Sattar N., Crilly A., Prach M., McCarey D.W., Payne H., Madhok R., Campbell C., Gracie J.A., Liew F.Y., McInnes I.B A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J. Immunol. 2003, 170:1524-1530.
21. Liu Z., Guo Z., Wang G., Zhang D., He H., Li G., Liu Y., Higgins D., Walsh A., Shanahan-Prendergast L., Lu J. Evaluation of the efficacy and safety of a statin/caffeine combination against H5N1, H3N2 and H1N1 virus infection in BALB/c mice. Eur. J. Pharm. Sci.: Off. J. Eur. Fed. Pharm. Sci. 2009, 38:215-223.
22. Maines T.R., Lu X.H., Erb S.M., Edwards L., Guarner J., Greer P.W., Nguyen D.C., Szretter K.J., Chen L.M., Thawatsupha P., Chittaganpitch M., Waicharoen S., Nguyen D.T., Nguyen T., Nguyen H.H., Kim J.H., Hoang L.T., Kang C., Phuong L.S., Lim W., Zaki S., Donis R.O., Cox N.J., Katz J.M., Tumpey T.M. Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J. Virol. 2005, 79:11788-11800.
23. Maines T.R., Szretter K.J., Perrone L., Belser J.A., Bright R.A., Zeng H., Tumpey T.M., Katz J.M. Pathogenesis of emerging avian influenza viruses in mammals and the host innate immune response. Immunol. Rev. 2008, 225:68-84.
24. Mortensen E.M., Restrepo M.I., Anzueto A., Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir. Res. 2005, 6:82.
25. Muller H.C., Hellwig K., Rosseau S., Tschernig T., Schmiedl A., Gutbier B., Schmeck B., Hippenstiel S., Peters H., Morawietz L., Suttorp N., Witzenrath M. Simvastatin attenuates ventilator-induced lung injury in mice. Crit. Care 2010, 14:R143.
26. Radigan K.A., Urich D., Misharin A.V., Chiarella S.E., Soberanes S., Gonzalez A., Perlman H., Wunderink R.G., Budinger G.R., Mutlu G.M. The effect of rosuvastatin in a murine model of influenza A infection. PLOS One 2012, 7:e35788.
27. Salomon R., Hoffmann E., Webster R.G. Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection. Proc. Nat. Acad. Sci. U.S.A. 2007, 104:12479-12481.
28. Szretter K.J., Gangappa S., Lu X., Smith C., Shieh W.J., Zaki S.R., Sambhara S., Tumpey T.M., Katz J.M. Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice. J. Virol. 2007, 81:2736-2744.
29. Tumpey T.M., Garcia-Sastre A., Mikulasova A., Taubenberger J.K., Swayne D.E., Palese P., Basler C.F. Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc. Nat. Acad. Sci. U.S.A. 2002, 99:13849-13854.
30. Vandermeer M.L., Thomas A.R., Kamimoto L., Reingold A., Gershman K., Meek J., Farley M.M., Ryan P., Lynfield R., Baumbach J., Schaffner W., Bennett N., Zansky S. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J. Infect. Dis. 2012, 205:13-19.
31. Walsh K.B., Teijaro J.R., Wilker P.R., Jatzek A., Fremgen D.M., Das S.C., Watanabe T., Hatta M., Shinya K., Suresh M., Kawaoka Y., Rosen H., Oldstone M.B. Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc. Nat. Acad. Sci. U.S.A. 2011, 108:12018-12023.
32. Wong Z.X., Jones J.E., Anderson G.P., Gualano R.C. Oseltamivir treatment of mice before or after mild influenza infection reduced cellular and cytokine inflammation in the lung. InfluenzaOther Respir. Viruses 2011, 5:343-350.